Details of the Drug-Related molecule(s) Interaction Atlas

General Information of Drug (ID: DMRSNEU)

Drug Name
Masitinib Drug Info
Synonyms
Masitinib; 790299-79-5; AB1010; Masatinib; Masitinib (AB1010); Masivet; AB-1010; AB 1010; UNII-M59NC4E26P; Masitinib [INN]; M59NC4E26P; 4-[(4-Methyl-1-piperazinyl)methyl]-N-[4-methyl-3-[[4-(3-pyridinyl)-2-thiazolyl]amino]phenyl]benzamide; CHEMBL1908391; CHEBI:63450; Masitinib (INN); N-(4-Methyl-3-((4-(pyridin-3-yl)thiazol-2-yl)amino)phenyl)-4-((4-methylpiperazin-1-yl)methyl)benzamide; Q-201339; C28H30N6OS; N-(4-methyl-3-(4-(pyridin-3-yl)thiazol-2-ylamino)phenyl)-4-((4-methylpiperazin-1-yl)methyl)benzamide
Indication
Disease Entry ICD 11 Status REF
Amyotrophic lateral sclerosis 8B60.0 Phase 3 [1]
Gastrointestinal stromal tumour 2B5B Phase 3 [2] , [1]
Metastatic gastric or gastroesophageal junction cancer 2D8Y Phase 3 [1]
Multiple sclerosis 8A40 Phase 3 [3]
Ovarian cancer 2C73 Phase 3 [2]
Pancreatic cancer 2C10 Phase 3 [2]
Cross-matching ID
PubChem CID
10074640
ChEBI ID
CHEBI:63450
CAS Number
CAS 790299-79-5
TTD Drug ID
DMRSNEU

Molecule-Related Drug Atlas

Molecule-Related Drug Atlas
Molecule Type:
DTT
Drug Status:
Approved Drug(s)
Clinical Trial Drug(s)
Patented Agent(s)
Download the Complete Related Drug List
Drug(s) Targeting Tyrosine-protein kinase (PTK)
Drug Name Drug ID Indication ICD 11 Highest Status REF
Baricitinib DM4ONW5 Rheumatoid arthritis FA20 Approved [4]
Asp-015K DMZ1UOI Psoriasis vulgaris EA90 Phase 3 [3]
PF-04965842 DM8J29L Atopic dermatitis EA80 Phase 3 [5]
KD019 DMEFW3G Brain metastases 2D50 Phase 2 [2]
LEO 124249 DM7W0JE Asthma CA23 Phase 2 [5]
ATI-502 DMK3VYU Atopic dermatitis EA80 Phase 2 [5]
TD-1473 DMJG7AY Ulcerative colitis DD71 Phase 1 [3]
Aminotriazolopyridine derivative 1 DMW2LZ0 N. A. N. A. Patented [6]
Imidazo[4,5-c]pyridine derivative 2 DMFDRJT N. A. N. A. Patented [6]
PMID27774824-Compound-Figure11Example1up DMH1W8F N. A. N. A. Patented [6]
⏷ Show the Full List of 10 Drug(s)
Drug(s) Targeting Proto-oncogene c-Src (SRC)
Drug Name Drug ID Indication ICD 11 Highest Status REF
Dasatinib DMJV2EK Chronic myelogenous leukaemia 2A20.0 Approved [7]
Bosutinib DMTI8YE Breast cancer 2C60-2C65 Approved [7]
SKI-758 DMQ8E9R Ischemia 8B10-8B11 Approved [8]
Herbimycin A DM6YWBF Solid tumour/cancer 2A00-2F9Z Approved [9]
Al3818 DM3WP0N Alveolar soft part sarcoma 2A60-2C35 Phase 3 [2]
CP-868596 DMZIM37 Gastrointestinal cancer 2C11 Phase 3 [2]
KX-01 DMF0NA9 Actinic keratosis EK90.0 Phase 3 [5]
Saracatinib DMBLHGP Hematologic tumour 2B33.Y Phase 2 [10]
TPX-0046 DMIVE67 Solid tumour/cancer 2A00-2F9Z Phase 1/2 [11]
ISIS-CRP DMQDUG4 Cardiovascular disease BA00-BE2Z Phase 1 [12]
⏷ Show the Full List of 10 Drug(s)

Molecular Interaction Atlas of This Drug

Molecular Interaction Atlas
Download the Complete Interaction Atlas for Visualization in Cytoscape

Drug Therapeutic Target (DTT)
DTT Name DTT ID UniProt ID MOA REF
Proto-oncogene c-Src (SRC) TT6PKBN SRC_HUMAN Inhibitor [3]
Tyrosine-protein kinase (PTK) TTJSQEF NOUNIPROTAC Inhibitor [2]

References

1 Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
2 Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
3 Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
4 2018 FDA drug approvals.Nat Rev Drug Discov. 2019 Feb;18(2):85-89.
5 Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
6 Inhibitors of JAK-family kinases: an update on the patent literature 2013-2015, part 1.Expert Opin Ther Pat. 2017 Feb;27(2):127-143.
7 A comparison of physicochemical property profiles of marketed oral drugs and orally bioavailable anti-cancer protein kinase inhibitors in clinical development. Curr Top Med Chem. 2007;7(14):1408-22.
8 Synthesis and Src kinase inhibitory activity of a series of 4-[(2,4-dichloro-5-methoxyphenyl)amino]-7-furyl-3-quinolinecarbonitriles. J Med Chem. 2006 Dec 28;49(26):7868-76.
9 In vivo antitumor activity of herbimycin A, a tyrosine kinase inhibitor, targeted against BCR/ABL oncoprotein in mice bearing BCR/ABL-transfected cells. Leuk Res. 1994 Nov;18(11):867-73.
10 Novel dual Src/Abl inhibitors for hematologic and solid malignancies.Expert Opin Investig Drugs.2010 Aug;19(8):931-45.
11 Clinical pipeline report, company report or official report of Turning Point Therapeutics.
12 The selectivity of protein kinase inhibitors: a further update. Biochem J. 2007 Dec 15;408(3):297-315.